✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Syncom Formulations (India) Ltd.

SYNCOMF

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹1,565 Cr.
P/E
27.19

Syncom Formulations (India) Ltd.

  • Syncom Formulations
  • Bliss GVS Pharma
  • Jagsonpal Pharma

FAQs on Syncom Formulations (India) Ltd. Shareprice

Syncom Formulations has given better returns compared to its competitors.
Syncom Formulations has grown at ~32.6% over the last 8yrs while peers have grown at a median rate of 27.67%

Syncom Formulations is not expensive.
Latest PE of Syncom Formulations is 27.18, while 3 year average PE is 46.12.
Also latest EV/EBITDA of Syncom Formulations is 25.94 while 3yr average is 43.76.

View FAQ's On Business

Growth Table

  • Syncom Formulations (India) Ltd.
  • Bliss GVS Pharma
  • Jagsonpal Pharma

Balance Sheet

  • Syncom Formulations (India) Ltd.
  • Bliss GVS Pharma
  • Jagsonpal Pharma

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Syncom Formulations (India) Ltd.
  • Bliss GVS Pharma
  • Jagsonpal Pharma

Cash Flow

  • Syncom Formulations (India) Ltd.
  • Bliss GVS Pharma
  • Jagsonpal Pharma

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Syncom Formulations (India) Ltd.
  • Bliss GVS Pharma
  • Jagsonpal Pharma

Quarterly Results

  • Syncom Formulations (India) Ltd.
  • Bliss GVS Pharma
  • Jagsonpal Pharma

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Syncom Formulations (India) Ltd. Financials

Balance sheet of Syncom Formulations is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Syncom Formulations is increasing.
Latest net debt of Syncom Formulations is ₹3.3 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹63 Crs.

Yes, profit is increasing.
The profit of Syncom Formulations is ₹57.56 Crs for TTM, ₹49.43 Crs for Mar 2025 and ₹25.31 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Syncom Formulations latest dividend payout ratio is 14.05% and 3yr average dividend payout ratio is 14.05%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech